Non-Hodgkin Lymphoma Therapeutics Market Research Report 2020 Radiant Insights, Inc
GBI Research, the leading business intelligence provider, has released its latest research, 'Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting', which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Non-Hodgkin Lymphoma (NHL). Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-hodgkin-lymphoma-therapeutics-in-asia-pacific-markets-to-2020-novel-technologies-show-considerable-promise-in-relapsed-refractory-setting The market in the APAC region was worth an estimated $1.1 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.6% to $1.7 billion in 2020. The expected launches of promising drugs, including novel protein kinase inhibitors and next-generation monoclonal antibodies, as well as the continued use of the current blockbuster, Rituxan/Mabthera, will be the key growth drivers. The launch of premium-priced novel glycol-engineered antibody; obinutuzumab; kinase inhibitors including idelalisib and ibrutinib; and the mTOR inhibitor everolimus are also expected to have a significant impact, as is the anticipated approval of immunomodulatory agent Revlimid as a maintenance setting. An increasingly aging population and a year-on-year increase in the number of incident cases will provide an additional boost. However, the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; and low access, penetration and price erosion due to generic dominance, especially in India, stand to curtail the APAC NHL market.
GBI Research, the leading business intelligence provider, has released its latest research, 'Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting', which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Non-Hodgkin Lymphoma (NHL).
Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-hodgkin-lymphoma-therapeutics-in-asia-pacific-markets-to-2020-novel-technologies-show-considerable-promise-in-relapsed-refractory-setting
The market in the APAC region was worth an estimated $1.1 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.6% to $1.7 billion in 2020. The expected launches of promising drugs, including novel protein kinase inhibitors and next-generation monoclonal antibodies, as well as the continued use of the current blockbuster, Rituxan/Mabthera, will be the key growth drivers. The launch of premium-priced novel glycol-engineered antibody; obinutuzumab; kinase inhibitors including idelalisib and ibrutinib; and the mTOR inhibitor everolimus are also expected to have a significant impact, as is the anticipated approval of immunomodulatory agent Revlimid as a maintenance setting. An increasingly aging population and a year-on-year increase in the number of incident cases will provide an additional boost. However, the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; and low access, penetration and price erosion due to generic dominance, especially in India, stand to curtail the APAC NHL market.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
4.2 Pipeline Analysis by Molecule Type 38<br />
4.3 Pipeline Analysis by Mechanism of Action 39<br />
4.4 Clinical Trials 41<br />
4.4.1 Failure Rate 41<br />
4.4.2 Patient Enrollment and Clinical Trial Size 42<br />
4.4.3 Duration 43<br />
4.5 Promising Drug Candidates in the Pipeline 44<br />
4.5.1 Idelalisib (GS-1101) - Gilead Sciences 44<br />
4.5.2 Imbruvica (Ibrutinib) - Pharmacyclics/Janssen Biotech 45<br />
4.5.3 Gazyva (Obinutuzumab) - Roche 45<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/non-hodgkinlymphoma-therapeutics-in-asia-pacific-markets-to-<strong>2020</strong>-novel-technologies-show-considerablepromise-in-relapsed-refractory-setting<br />
4.5.4 Revlimid (lenalidomide) - Celgene 46<br />
4.5.5 Afinitor (everolimus) - Novartis 47<br />
4.6 Heat Map of Safety and Efficacy and Product Competitiveness Framework for <strong>Non</strong>-<strong>Hodgkin</strong><br />
<strong>Lymphoma</strong> Pipeline 48<br />
5 <strong>Market</strong> Forecast to <strong>2020</strong> 51<br />
5.1 Geographical <strong>Market</strong>s 51<br />
5.1.1 APAC <strong>Market</strong> 51<br />
5.1.2 India 52<br />
5.1.3 Australia 55<br />
5.1.4 China 58<br />
5.1.5 Japan 60<br />
5.2 Drivers and Barriers for the Disease <strong>Market</strong> 63<br />
5.2.1 Drivers 63<br />
5.2.2 Barriers 64
Change language